Biomarker ID | 16 |
PMID | 15067324 |
Year | 2004 |
Biomarker | PPFIA3+COPEB+FOS+JUNB+ZFP36 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Differentially Expressed in Recurrent Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Recurrence Vs No Recurrence |
Type of Biomarker | Prognostic |
Cohort | 21 patients were divided into two subgroups representing prostate cancer with recur- rent (8 patients) and nonrecurrent (13 patients). Validation set consisted of 79 patients with 37 recurrent and 42 non recurrent) |
Senstivity | Recurrent Cancer Prediction: 75% |
Specificity | Non Recurrent Cancer Prediction: 92% |
AUC | NA |
Accuracy | 86% |
Level Of Significance | p=0.001 |
Method Used | RNeasy or Fast-Tract kits |
Clinical | No |
Remarks | Results shown for Training Set |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | PPFIA3, KLF6, FOS, JUNB, ZFP36 |